Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • H2S, Persulfidation, and Ferroptosis in NSCLC

    2026-10-06

    H2S, Persulfidation, and Ferroptosis in NSCLC

    Ferroptosis is an iron- and lipid peroxidation-dependent form of regulated cell death that has attracted interest as a possible vulnerability in cancer. The 2024 study by Zheng and colleagues adds a metabolic layer to this field by showing how hydrogen sulfide (H2S) can influence ferroptosis sensitivity in non-small cell lung cancer (NSCLC). Rather than treating H2S only as a gaseous signaling metabolite, the paper places it within a pathway connecting protein persulfidation, homocysteine metabolism, cysteine availability, glutathione production, and ferroptotic stress. The reference study is published in Molecular Cell (Zheng et al., 2024).

    Study Background and Research Question

    Ferroptosis is characterized by the accumulation of lipid reactive oxygen species and iron-dependent oxidative damage, together with distinctive changes in cellular morphology. Cancer cells may be particularly sensitive because rapid proliferation can increase iron demand, oxidative pressure, and dependence on antioxidant systems. The supplied reference describes additional vulnerability in drug-resistant or mesenchymal tumor states, where survival may rely more heavily on glutathione peroxidase 4 (GPX4), an enzyme that limits lipid peroxidation.

    Cystine availability is central to this defense system. Imported cystine supports intracellular cysteine production, and cysteine is required for glutathione synthesis. Glutathione, in turn, supports GPX4-mediated control of lipid peroxides. Consequently, conditions that reduce cystine uptake or availability can weaken antioxidant capacity and promote ferroptosis. The paper focuses on an important unresolved question: how does H2S alter the metabolic state that determines whether NSCLC cells withstand or undergo ferroptotic stress?

    The study specifically examines whether H2S affects the transsulfuration pathway and whether that effect explains increased ferroptosis under low-cystine conditions. This question is significant because transsulfuration connects sulfur amino acid metabolism with the supply of cysteine and other redox-relevant metabolites.

    Key Innovation from the Reference Study

    The central innovation is the identification of S-adenosyl homocysteine hydrolase (SAHH) as a functional target of H2S-mediated persulfidation. According to Zheng et al., H2S persulfidates the 195th cysteine residue of SAHH and reduces the enzyme’s activity. This provides a direct molecular explanation for how H2S can reshape homocysteine metabolism rather than merely correlating with changes in ferroptosis sensitivity.

    That finding links three previously separable concepts. First, H2S acts through a covalent cysteine modification, persulfidation. Second, the modified protein is an enzyme positioned within homocysteine metabolism. Third, the metabolic consequence is connected to the cellular cysteine and glutathione pools that influence ferroptosis. The proposed chain is therefore H2S signaling, SAHH persulfidation, reduced SAHH activity, lower homocysteine, reduced cysteine and glutathione under cystine-depleted conditions, and greater ferroptotic susceptibility.

    The importance of this result is conceptual as well as mechanistic. It suggests that ferroptosis sensitivity is not determined only by the immediate availability of cystine or the activity of GPX4. It can also be shaped by sulfur metabolism and post-translational modification of a metabolic enzyme. This expands the regulatory landscape that researchers may need to consider when interpreting ferroptosis phenotypes in NSCLC.

    Conceptual Study Design and Evidence Scope

    The supplied paper uses a multi-level mechanistic framework. At the cellular level, the study assesses whether H2S increases the response of human NSCLC cells to ferroptotic stress, particularly when cystine is limited. At the metabolic level, it examines changes in homocysteine, cysteine, and glutathione. At the protein level, it investigates whether SAHH is persulfidated and whether this modification is associated with reduced enzymatic activity.

    This structure is important because it moves beyond a single endpoint. A change in cell viability alone would not establish whether H2S directly regulates ferroptosis or produces nonspecific toxicity. The reported integration of ferroptosis phenotypes, metabolite changes, SAHH activity, and site-specific persulfidation provides a more coherent mechanistic argument. The findings are also framed around cystine availability, allowing the authors to test whether H2S has a context-dependent effect rather than a uniform effect across metabolic states.

    The evidence should nevertheless be interpreted according to the scope described in the source. The paper establishes a mechanistic relationship in NSCLC models and reports implications for ferroptosis-based cancer treatment. It does not, from the supplied summary alone, establish clinical efficacy or define a broadly applicable biomarker strategy. The study is best understood as a preclinical mechanism paper that proposes how sulfur metabolism can regulate ferroptotic vulnerability.

    Core Findings and Why They Matter

    H2S increases ferroptotic vulnerability when cystine is limited

    Zheng et al. report that H2S promotes ferroptosis induced by cystine depletion in NSCLC cells. The effect is described as particularly evident under low-cystine conditions, which is consistent with the established importance of cysteine and glutathione in controlling lipid peroxidation. In this setting, H2S appears to function as a sensitizing factor rather than simply as an independent cell-death trigger.

    This distinction matters for interpretation. A sensitizer may have its strongest effect when a tumor cell is already close to the limit of its antioxidant capacity. The results therefore support a model in which H2S changes the threshold for ferroptosis, making cystine stress more consequential for NSCLC cells.

    SAHH is a metabolic control point for the response

    The study identifies SAHH as the molecular connection between H2S signaling and homocysteine metabolism. Persulfidation at cysteine 195 is reported to reduce SAHH activity. Reduced activity is associated with decreased homocysteine levels, which the authors connect to downstream reductions in cysteine and glutathione under cystine-depleted conditions (Zheng et al., 2024).

    This result is meaningful because it assigns a specific enzymatic consequence to H2S-mediated persulfidation. Persulfidation is often discussed as a broad regulatory modification, but the paper presents a defined example in which modification of a particular cysteine residue changes the activity of a metabolic enzyme and influences a cell-death phenotype.

    Reduced sulfur buffering helps explain the ferroptosis phenotype

    Cysteine and glutathione are essential components of the cellular response to oxidative stress. By reporting lower levels of these metabolites in the relevant low-cystine context, the study offers a biochemical explanation for why H2S increases ferroptotic sensitivity. The interpretation is not that H2S universally depletes glutathione in every biological setting, but that its effect becomes consequential when cystine supply is already constrained.

    The findings also help connect transsulfuration with ferroptosis. The transsulfuration pathway is commonly viewed as a route for balancing sulfur amino acid metabolism and supporting cysteine production. The paper instead shows that H2S, described as a metabolite of this pathway, can feed back on the pathway through persulfidation of SAHH. This creates a regulatory loop in which sulfur metabolism influences the redox defenses that determine ferroptosis susceptibility.

    Implications for ferroptosis-based cancer research

    The authors conclude that H2S can enhance ferroptosis-based cancer therapies for NSCLC. At the level of research interpretation, the finding suggests that metabolic state may be an important determinant of response to cystine-depletion strategies or other approaches that increase lipid peroxidation. It also raises the possibility that SAHH modification or related sulfur-metabolism signatures could help explain heterogeneous responses among tumor models.

    These implications remain preclinical. The paper supports a mechanistic rationale for studying H2S and SAHH in the context of ferroptosis, but it does not by itself demonstrate that manipulating this pathway will be effective or safe in patients.

    Comparison with Existing Internal Articles

    No internal articles were provided for comparison or interlinking. Accordingly, this article treats Zheng et al. as the primary evidence source and does not introduce unrelated product or pathway claims. For researchers comparing this work with other literature, the most relevant distinction is its focus on persulfidation of a defined metabolic enzyme rather than on ferroptosis regulation through GPX4, cystine transport, or iron handling alone.

    Limitations and Transferability

    The supplied findings support a clear mechanistic model, but several boundaries should guide interpretation. First, the evidence described is centered on NSCLC cells and low-cystine conditions. The strength of the mechanism across other tumor types, normal lung cells, or tissues with different sulfur-metabolism states remains to be established.

    Second, ferroptosis is a context-dependent phenotype. Changes in lipid composition, iron handling, GPX4 dependence, antioxidant buffering, and nutrient availability can all influence the response. H2S effects observed in one cellular background may therefore not predict responses in another. The paper’s emphasis on cystine status is an important reminder that the same signaling metabolite can have different consequences under different nutrient conditions.

    Third, the mechanistic findings do not automatically establish therapeutic selectivity. A pathway that increases oxidative stress in tumor cells could also affect nonmalignant cells, depending on exposure, metabolic reserve, and tissue context. The supplied summary does not provide enough information to assess the breadth of model systems, pharmacological exposure relationships, long-term tolerability, or clinical translation.

    Finally, the reported link between SAHH persulfidation and ferroptosis should be distinguished from a complete account of ferroptosis regulation. The study identifies an important regulatory axis, but additional pathways may determine whether altered homocysteine metabolism produces lipid peroxidation, irreversible cell injury, or adaptation. Independent validation of the modification site, pathway dependence, and relevance across models would strengthen transferability.

    Research Support Resources

    The primary source for this interpretation is Zheng et al., Hydrogen sulfide-mediated persulfidation regulates homocysteine metabolism and enhances ferroptosis in non-small cell lung cancer. Researchers can also review Evacetrapib (LY2484595), SKU A4377, as a separately listed research material in the supplied product dossier. The provided reference text does not identify evacetrapib as a study material or establish a role for it in the reported H2S–SAHH mechanism.